Table 1.
Sub-populations of the “Benefit Cohort Population.”
Figure 1.
General formula for calculating economic benefits.
The formula was applied and calculated independently for each country to accommodate country-specific differences in several key parameters (i.e. life expectancy, mortality rate, direct and indirect costs). All calculated costs and benefits are discounted by 3% per year to the base year of 2008.
Figure 2.
Duration of economic benefits.
Economic benefits are calculated only for the benefit cohort population receiving MDA between 2000–2007; however, the benefits are gained until the end of their lifetime. For modeling purposes, single average ages were used to encompass the entire age range of individuals in each population subgroup, realizing that some individuals will be above this average age at the time of treatment, and some below. The size of each subgroup decreases each year based on country and age-specific mortality rates.
Table 2.
Benefit Cohort Population: Individuals and person-years.
Table 3.
Epidemiological and cost estimates used in the Economic Benefit Model.
Table 4.
GPELF MDA treatments (2000–2007).
Table 5.
Total costs prevented over lifetime of Benefit Cohort Population.
Table 6.
Total costs prevented per individual of the Benefit Cohort Population.
Figure 3.
Total Economic benefits by category.
The total economic benefit for individuals (i.e. excluding health system savings) of US$21.8 billion can be further analyzed by cost type, morbidity type, and clinical presentation.
Table 7.
Lifetime economic benefits by region.
Figure 4.
Cumulative economic benefits resulting from the first 8 years of the GPELF.
Total economic savings to individuals and health systems accumulate throughout the benefit cohort population's lifetime.
Table 8.
Health system economic benefits.
Table 9.
Sensitivity analysis for chronic disease reversal following MDA.
Table 10.
Country-specific benefit-cost ratios.
Figure 5.
Potential economic impact of the GPELF.
Indicates the economic benefit already achieved and the potential benefit remaining should the GPELF reach all endemic countries and at-risk populations.